Business Context and Reporting Period
Company: Enlivex Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2022 (Specifically December 30, 2022)
Context: The filing announces the entry into an "At-The-Market" (ATM) equity offering agreement to raise capital through the sale of ordinary shares.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data (revenue, profit, cash flow, margins, or debt levels) for the period.
- Proposed Offering Size: Up to $100.0 million in aggregate offering price.
- Underwriting Commission: 3.0% of the gross sales price of shares sold.
- Share Class: Ordinary shares, par value NIS 0.40 per share.
Material Changes
The primary material change is the execution of a Sales Agreement with Cantor Fitzgerald & Co. and JMP Securities LLC as agents. This agreement enables the company to sell shares on an as-needed basis through existing trading markets (e.g., Nasdaq Capital Market) or via negotiated transactions, subject to the company's discretion.
Guidance, Outlook, and Risks
Management Commentary: The company is not obligated to sell any shares under the agreement. Sales will be made based on instructions from the company, including price or size limits.
Terms and Conditions:
- The agreement terminates upon the sale of all offered shares or earlier termination by either party.
- The company must reimburse agents for certain specified expenses.
- The filing incorporates the full text of the Sales Agreement (Exhibit 10.1) for complete terms.
Risks: The filing notes that no offer or sale of securities will occur in any state where such action would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the current market price of Enlivex ordinary shares to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific conditions and termination rights.
- Monitor future filings (Form 8-K or 6-K) to track actual share sales and proceeds generated under this ATM facility.
- Check the company's latest Form 20-F for current cash position and liquidity needs driving this offering.